---
title: "JSNE released its first-quarter performance, with a net profit attributable to the parent company of 164 million yuan, a year-on-year decrease of 34.65%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/236978357.md"
description: "JSNE released its Q1 2025 performance report, with operating revenue of 574 million yuan, a year-on-year decrease of 13.85%; net profit attributable to the parent company of 164 million yuan, a year-on-year decrease of 34.65%; net profit after deducting non-recurring gains and losses of 160 million yuan, a year-on-year decrease of 34.70%; basic earnings per share of 0.18 yuan/share"
datetime: "2025-04-22T12:45:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236978357.md)
  - [en](https://longbridge.com/en/news/236978357.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236978357.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/236978357.md) | [English](https://longbridge.com/en/news/236978357.md)


# JSNE released its first-quarter performance, with a net profit attributable to the parent company of 164 million yuan, a year-on-year decrease of 34.65%

According to the Zhitong Finance APP, JSNE (603693.SH) released its first quarter report for 2025. The company's operating revenue for the first quarter of 2025 was 574 million yuan, a year-on-year decrease of 13.85%; the net profit attributable to shareholders of the listed company was 164 million yuan, a year-on-year decrease of 34.65%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 160 million yuan, a year-on-year decrease of 34.70%; the basic earnings per share were 0.18 yuan/share

### 相關股票

- [JSNE (603693.CN)](https://longbridge.com/zh-HK/quote/603693.CN.md)

## 相關資訊與研究

- [Great Wall Motor (SEHK:2333) Valuation Check After March Sales And Production Growth](https://longbridge.com/zh-HK/news/281642332.md)
- [IL&FS Engineering Discloses Full Default on Bank Loans Totaling ₹2,627 Crore](https://longbridge.com/zh-HK/news/281691566.md)
- [Raising Cane's CEO says he doesn't care for this one menu item, but had to sell it anyway](https://longbridge.com/zh-HK/news/281466981.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [BYD Mar NEV sales rebound to over 300,000 as overseas growth accelerates](https://longbridge.com/zh-HK/news/281361123.md)